Press Releases
November 05, 2015
Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)
"We are encouraged by the preliminary findings seen in Phase 1 of our first company-sponsored trial and look forward to presenting the data in a peer-reviewed setting," said Dr. Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. "Additional biomarker data to be presented will further the understanding of pharmacodynamic mechanisms of KTE-C19 and the importance of optimizing the conditioning chemotherapy regimen prior to KTE-C19 therapy."
The accepted abstracts are listed below and are now available online on the ASH conference website: https://ash.confex.com/ash/2015/webprogram/start.html
2015 ASH Annual Meeting Presentations
Title: Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
Date:
Session: 801. Gene Therapy and Transfer: Poster I
Abstract number: 2042
Location:
Presenter:
Title: Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Date:
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Abstract number: 2730
Location:
Presenter: Sattva S. Neelapu, M.D., The University of Texas MD Anderson Cancer Center,
Title: Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Date:
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
Abstract number: 3991
Location:
Presenter:
Title: Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy
Date:
Session: 801. Gene Therapy and Transfer: Poster III
Abstract number: 4426
Location:
Presenter:
About Kite Pharma, Inc.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the progress and success of the Phase 2 portion of the clinical trial of KTE-C19. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
CONTACT:Kite Pharma :Cynthia M. Butitta , Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media:Justin Jackson For Investor Inquiries:Lisa Burns Burns McClellan 212-213-0006 jjackson@burnsmc.com lburns@burnsmc.com
Source:
News Provided by Acquire Media